is bigger than the vision of current leadership. It always has been. But the diagnostic market is so competetive and interdependent on reagents, that the profit margin is always being squeezed. The DPP format needs to be developed into a new category for testing health and safety conditions. It is so obvious to any diagnostician. The search should have been for unique, proprietary reagents (antigens, reactive molecules and their markers).
I only hope that new leadership will lead to optimum application of the technology.